首頁 › 肺癌 › 印第安納 › Indianapolis
Indianapolis, IN 的 肺癌 臨床試驗
16 項針對 肺癌 的研究正在 Indianapolis（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
招募中3 期
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Saint Catherine Hospital, Indianapolis
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
招募中3 期
- Saint Catherine Hospital, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · 距離 13 英里
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
招募中1 期
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- Indiana University Health University Hospital, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- Community Health Network, Indianapolis
Increasing Equity in Lung Cancer Screening
招募中歡迎健康志工
- Eskenazi Health, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
招募中觀察性研究
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Roudebush VA Medical Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
招募中1/2 期
- University of Indiana, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
招募中2 期
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
招募中
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Nashville, TN40 項研究
- Baltimore, MD40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
Indianapolis 的其他研究
- 非小細胞肺癌32 項研究
- 癌症（所有類型）24 項研究
- 心臟衰竭23 項研究
- 肥胖症20 項研究
- 乳癌20 項研究
- 轉移性癌症19 項研究
- 大腸直腸癌18 項研究
- 卵巢癌17 項研究
- 心血管疾病17 項研究
- 第一型糖尿病14 項研究
- 子宮內膜癌14 項研究
- 阿茲海默症14 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。